001     163435
005     20240320115518.0
024 7 _ |a 10.1111/ene.15302
|2 doi
024 7 _ |a pmid:35212083
|2 pmid
024 7 _ |a 1351-5101
|2 ISSN
024 7 _ |a 1468-1331
|2 ISSN
024 7 _ |a 1471-0552
|2 ISSN
024 7 _ |a altmetric:124060371
|2 altmetric
037 _ _ |a DZNE-2022-00195
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hermann, Peter
|0 P:(DE-2719)2812183
|b 0
|u dzne
245 _ _ |a Plasma neurofilament light chain as a biomarker for fatal familial insomnia.
260 _ _ |a Oxford
|c 2022
|b Blackwell Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1655201134_926
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a ISSN 1468-1331 not unique: **2 hits**. (CC BY-NC)
520 _ _ |a Fatal familial insomnia is a rare hereditary prion disease associated with the D178N-129M PRNP mutation. Early diagnosis is difficult, because the clinical syndrome may overlap with affective disorders. In addition, most known cerebrospinal fluid biomarkers for prion diseases and magnetic resonance imaging do not show a good diagnostic accuracy for fatal familial insomnia. In this context, data on plasma biomarkers are scarce.We analyzed levels of neurofilament light chain, glial fibrillary acidic protein, chitinase-3-like protein 1, calcium-binding protein B, and total tau protein in six serial plasma samples from a patient with fatal familial insomnia. Subsequently, plasma neurofilament light chain was analyzed in n = 25 patients and n = 19 controls. The diagnostic accuracy and associations with disease stage and duration were explored.Among all biomarker candidates in the case study, only neurofilament light chain levels showed a constant evolution and increased over time. They discriminated fatal familial insomnia from controls with an area under the curve of 0.992 (95% confidence interval [CI] = 0.974-1) in the case-control study. Higher concentrations were associated with methionine homozygosity at codon 129 PRNP (p = 0.006), shorter total disease duration (rho = -0.467, p = 0.019, 95% CI = -0.790 to -0.015), and shorter time from sampling to death (rho = -0.467, p = 0.019, 95% CI = -0.773 to -0.019).Plasma neurofilament light chain may be a valuable minimally invasive diagnostic biomarker for fatal familial insomnia after clinical onset. Most important, stage-related increase and association with disease duration indicate potential as a prognostic marker and as a surrogate marker in clinical trials.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
542 _ _ |i 2022-03-07
|2 Crossref
|u http://creativecommons.org/licenses/by-nc/4.0/
542 _ _ |i 2022-03-07
|2 Crossref
|u http://doi.wiley.com/10.1002/tdm_license_1.1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a biomarker
|2 Other
650 _ 7 |a fatal familial insomnia
|2 Other
650 _ 7 |a neurofilament light chain
|2 Other
650 _ 7 |a plasma
|2 Other
650 _ 7 |a prion disease
|2 Other
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Case-Control Studies
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Insomnia, Fatal Familial: diagnosis
|2 MeSH
650 _ 2 |a Insomnia, Fatal Familial: genetics
|2 MeSH
650 _ 2 |a Intermediate Filaments
|2 MeSH
650 _ 2 |a Prion Diseases: genetics
|2 MeSH
700 1 _ |a Canaslan, Sezgi
|0 P:(DE-2719)9001944
|b 1
|u dzne
700 1 _ |a Villar-Piqué, Anna
|0 P:(DE-2719)9000327
|b 2
|u dzne
700 1 _ |a Bunck, Timothy
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Goebel, Stefan
|0 P:(DE-2719)9001986
|b 4
|u dzne
700 1 _ |a Llorens Torres, Francesc Josep
|0 P:(DE-2719)2811280
|b 5
|u dzne
700 1 _ |a Schmitz, Matthias
|0 P:(DE-2719)9000287
|b 6
|u dzne
700 1 _ |a Zerr, Inga
|0 P:(DE-2719)2000058
|b 7
|e Last author
|u dzne
773 1 8 |a 10.1111/ene.15302
|b Wiley
|d 2022-03-07
|n 6
|p 1841-1846
|3 journal-article
|2 Crossref
|t European Journal of Neurology
|v 29
|y 2022
|x 1351-5101
773 _ _ |a 10.1111/ene.15302
|g p. ene.15302
|0 PERI:(DE-600)2020241-6
|n 6
|p 1841-1846
|t European journal of neurology
|v 29
|y 2022
|x 1351-5101
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/163435/files/DZNE-2022-00195.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/163435/files/DZNE-2022-00195.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:163435
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-2719)2812183
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 1
|6 P:(DE-2719)9001944
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-2719)9000327
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)9001986
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 5
|6 P:(DE-2719)2811280
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 6
|6 P:(DE-2719)9000287
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2000058
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NEUROL : 2021
|d 2022-11-11
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NEUROL : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1440011-1
|k AG Zerr
|l Translational Studies and Biomarkers
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1440011-1
980 1 _ |a FullTexts
999 C 5 |9 -- missing cx lookup --
|a 10.1111/j.1750-3639.1998.tb00176.x
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1136/jnnp-2013-305978
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S1474-4422(20)30477-4
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1093/brain/awab350
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1093/brain/awl003
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1136/jnnp-2020-323826
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1186/s13195-021-00815-6
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1038/s41380‐021‐01045‐w
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1038/s41582-018-0058-z
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.jalz.2017.12.008
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1002/ana.25300
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1186/s12916-020-01608-8
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1001/jamaneurol.2019.0765
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.3389/fgene.2019.00895
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S1474-4422(19)30403-X
|2 Crossref


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21